STAT3 and STAT6 polymorphisms predict the severity of adverse reactions in Chinese NSCLC patients receiving EGFR-TKIs therapy.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of chemotherapy"
DOI: 10.1080/1120009x.2023.2203610
Abstract: A total of 162 non-small cell lung cancer (NSCLC) patients were divided into discovery (N = 68) and validation (N = 94) groups. Nine Janus kinase/Signal transducer and activator of transcription (JAK/STAT) pathway-related single nucleotide polymorphisms were selected to… read more here.
Keywords: egfr tkis; nsclc patients; stat6; group ... See more keywords